Grant C. Bogle - 02 Feb 2022 Form 4 Insider Report for Epizyme, Inc.

Role
President and Chief Executive Officer, Director
Signature
/s/ John Weidenbruch, attorney-in-fact
Issuer symbol
N/A
Transactions as of
02 Feb 2022
Net transactions value
$0
Form type
4
Filing time
04 Feb 2022, 15:15:24 UTC
Previous filing
18 Aug 2021
Next filing
21 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EPZM Common Stock, par value $0.0001 Award $0 +87,500 +92% $0.000000 183,060 02 Feb 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EPZM Stock Option (Right to Buy) Award $0 +417,500 $0.000000 417,500 02 Feb 2022 Common Stock 417,500 $1.41 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of shares of Common Stock issuable under 87,500 restricted stock units ("RSUs") granted pursuant to the Company's 2013 Stock Incentive Plan. Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in three equal installments, with the first installment vesting on August 16, 2022, the second installment vesting on August 16, 2023, and the third installment vesting on August 16, 2024.
F2 This option was granted on February 2, 2022 pursuant to the Company's 2013 Stock Incentive Plan with respect to 417,500 shares of Common Stock, with 33.33% vesting on August 16, 2022 and the remaining 66.67% vesting in 24 substantially equal monthly installments thereafter.

Remarks:

President and Chief Executive Officer